Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...
H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
product in the US – and Hikma Pharma’s Kloxxado. FDA Commissioner Robert Califf said the approval “places a new prescription opioid reversal option in the hands of communities, harm ...
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose ...
The pharmaceutical company recently secured exclusive rights to KLOXXADO nasal spray in the U.S. and Canada, complementing its existing portfolio of opioid overdose treatments. This move is part of ...
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ...
Under the terms of the agreement, Hikma will continue to manufacture KLOXXADO® Nasal Spray 8 mg, which will be integrated into Emergent’s proprietary NARCANDirect™ distribution network.
The pharmaceutical company recently secured exclusive rights to KLOXXADO nasal spray in the U.S. and Canada, complementing its existing portfolio of opioid overdose treatments. This move is part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback